secwatch.observer — SEC 8-K summary
======================================

Issuer:     TALPHERA, INC. (TLPH)
CIK:        0001427925
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001437749-25-016840
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talphera Q1 2025 net loss narrows to $0.10/share; NEPHRO study reduced to 70 patients
--------------------------------------------------------------------------------

- Net loss from continuing ops $2.7M vs $4.0M YoY; diluted EPS loss $0.10 vs $0.16.
- Cash $5.4M at March 31; adjusted to $9.8M after $4.4M net proceeds from April financing tranche.
- FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; primary endpoint powered at 90%.
- Three new clinical sites activated in 2025; five more expected by mid-year for total of 13.
- 2025 cash operating expense guidance $17-19M, including completing registration trial by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925016840/0001437749-25-016840-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1427925/000143774925016840/acrx20250513_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016840

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer